Skip to content
OpenCapital
Get started

OS Therapies OSTX Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate at other companies

CTO
Citius Oncology, Inc.CTOR
4.7%+0.6pp

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M—
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K—
Free cash flow-$3.7M—

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M—

Returns & leverage

See full
Return on equity470%—
Debt / equity-1.8×—
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's share based compensation arrangement by share based payment award fair value assumptions risk free interest rate.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's share based compensation arrangement by share based payment award fair value assumptions risk free interest rate?
OS Therapies (OSTX) reported share based compensation arrangement by share based payment award fair value assumptions risk free interest rate of 3.8% in Q1 2026.
What does share based compensation arrangement by share based payment award fair value assumptions risk free interest rate mean?
The risk-free interest rate applied in valuation models to estimate the fair value of share-based compensation awards. This rate is typically based on government bond yields and impacts the overall compensation expense recognized by the company.